Literature DB >> 3893253

Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes.

D C Simonson, W V Tamborlane, R A DeFronzo, R S Sherwin.   

Abstract

Counterregulatory hormone responses to hypoglycemia were examined in six healthy controls and in six patients with type I diabetes before and after 4 to 8 months of insulin pump treatment. The insulin clamp technique was used to provide an identical hypoglycemic stimulus (about 50 mg/dL) in each study group. Before pump treatment, the release of counterregulatory hormones (except glucagon) during the hypoglycemic period was not significantly different in diabetics from that in normal controls. However, when values before and after pump treatment in diabetics were compared, there were significant reductions in epinephrine (304 +/- 70 and 127 +/- 43 pg/mL; p less than 0.01), growth hormone (45 +/- 12 and 18 +/- 5 ng/mL; p less than 0.05), and cortisol (20 +/- 3 and 10 +/- 2 micrograms/dL; p less than 0.01) levels during hypoglycemia. Defective glucagon release during hypoglycemia in the diabetics was not corrected by pump treatment. Intensive insulin treatment of patients with type I diabetes causes a generalized reduction in counterregulatory hormone release after a moderate fall in blood glucose levels. This reduction may impair glucose counterregulation and diminish perception of hypoglycemia, thereby increasing the risk of hypoglycemic episodes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893253     DOI: 10.7326/0003-4819-103-2-184

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

1.  Adaptation to mild hypoglycaemia in normal subjects despite sustained increases in counter-regulatory hormones.

Authors:  D Kerr; I A Macdonald; R B Tattersall
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

Review 2.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Hypoglycemia--a major risk of insulin therapy.

Authors:  K R Feingold
Journal:  West J Med       Date:  1991-04

4.  Cognitive function during hypoglycemia in type I diabetes mellitus.

Authors:  B M Frier
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-29

5.  Continuous glucose monitoring in subjects after simultaneous pancreas-kidney and kidney-alone transplantation.

Authors:  Luisa M Rodríguez; Richard J Knight; Rubina A Heptulla
Journal:  Diabetes Technol Ther       Date:  2010-05       Impact factor: 6.118

6.  Adrenergic system and carbohydrate metabolism. Effects of beta-receptor blockade on insulin secretion and peripheral insulin sensitivity in normoglycaemic patients.

Authors:  L A Ferrara; B Capaldo; A Rivellese; S Genovese; C Iovine; P Mastranzo; F Cirillo; M Mancini
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Factors influencing the effectiveness of glucagon for preventing hypoglycemia.

Authors:  Jessica R Castle; Julia M Engle; Joseph El Youssef; Ryan G Massoud; W Kenneth Ward
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

Review 8.  Adverse effects of exogenous insulin. Clinical features, management and prevention.

Authors:  A W Patrick; G Williams
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

9.  Glucose counterregulation in type 1 diabetic patients with decreased symptoms of hypoglycemia after insulin pump treatment.

Authors:  A Hübinger; K Wiefels; D Ziegler; F A Gries
Journal:  Klin Wochenschr       Date:  1991-10-31

10.  Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness.

Authors:  T S Trovik; R Jaeger; R Jorde; G Sager
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.